News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Media
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsShortsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Radiation Oncology|
Surgery
Advertisement

Manuel González Barón, MD

Advertisement

Articles by Manuel González Barón, MD

The UFT/Leucovorin/Etoposide Regimen for the Treatment of Advanced Gastric Cancer

ByManuel González Barón, MD,Enrique Espinosa, MD,Jaime Feliu, MD,Amalio Ordóñez, MD,Pilar Zamora, MD,Javier De Castro, MD,Carlos García Girón, MD,Pilar García Alfonso, MD,Pilar Garrido, MD,Joaquin Belón, MD,Maria Lomas, MD
September 2nd 1997

Gastric cancer is the most chemosensitive adenocarcinoma among digestive neoplasms. A few years ago, we performed a phase II trial with the FLEP regimen, in which fluorouracil (5-FU) and leucovorin are combined

Advertisement

Latest Updated Articles

  • The UFT/Leucovorin/Etoposide Regimen for the Treatment of Advanced Gastric Cancer
    The UFT/​Leucovorin/​Etoposide Regimen for the Treatment of Advanced Gastric Cancer

    September 2nd 1997



Advertisement
Advertisement

Trending on CancerNetwork

1

FDA Approves Ruxolitinib Tablets for Hematologic Malignancies

2

How Effective and Safe is EUS-Guided Alpha DaRT in Pancreatic Cancer?

3

Unraveling Daraxonrasib’s Breakthrough in Metastatic Pancreatic Cancer

4

SLN Surgery Omission Does Not Increase Radiotherapy Use in Breast Cancer

5

Treatment of Patients with FLT3-ITD+ Acute Myeloid Leukemia in Three Phases

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Editorial
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us